Press

Clearmind Medicine Announces Share-Based Payment for the Company’s Consultants

Jul 18 • 1 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has issued 17,899 common shares in the capital of the Company (“Shares”) in lieu of the final payment of $10,000, starting May 1st 2022, to consultants…

Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq

Jul 17 • 9 min read

Incannex Healthcare Limited (NASDAQ: IXHL / ASX: IHL), is pleased to announce its intention to redomicile from Australia to the United States via proposed schemes of arrangement (Schemes) between Incannex and its shareholders (Share Scheme) and Incannex and its optionholders (Option Scheme). Implementation of the Schemes is subject to approval of IHL’s shareholders (in respect of the Share Scheme)…

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology

Jul 17 • 3 min read

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that positive data from an open-label phase 2 clinical trial of investigational COMP360 psilocybin in addition to daily selective serotonin reuptake inhibitors (SSRIs) in treatment-resistant depression has been published online in the peer reviewed…

Filament Health Announces Change of Auditor

Jul 17 • 2 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company today announced a change of auditor from Crowe MacKay LLP (the “Former Auditor“) to MNP LLP (the “Successor Auditor“). At the request of the Company, the Former Auditor resigned as the auditor of the Company effective July 14, 2023 and the…

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Jul 17 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, announces a non-brokered private placement for gross proceeds of CDN$205,000 (the “Offering”) of units (the “Units”) at an issue price of CDN$0.20 per Unit. Each Unit will consist of one Class A common share in the capital of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441